Arbutus Biopharma's Upcoming Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS) is making significant strides as a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (cHBV) infection. With a strong emphasis on utilizing their extensive virology expertise, the company has announced its participation in two major investor conferences taking place soon in New York.
Conference Details
The management team at Arbutus is preparing to host one-on-one meetings during these important events:
H.C. Wainwright 26th Annual Global Investment Conference
On September 9 at 8:00 am ET, Arbutus will deliver a formal presentation at this conference. This event will serve as a platform for Arbutus to showcase its innovative strategies and advancements in treatment options.
Baird Global Healthcare Conference
The next day, September 10, Arbutus will participate in a fireside chat at 8:30 am ET, offering further insights into their research and future developments within the virology field.
Accessing the Presentations
For those who wish to follow along, live webcasts will be available during these presentations. Additionally, an archived replay will be accessible for a limited time after the events, ensuring that even those who cannot attend live can stay updated on Arbutus Biopharma's progress.
About Arbutus Biopharma Corporation
Arbutus is committed to tackling the complex challenge of developing a functional cure for chronic hepatitis B. Their strategic approach involves suppressing HBV DNA, lowering surface antigen levels, and stimulating HBV-specific immune responses to create a comprehensive treatment plan. The company’s pipeline features promising candidates such as the RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101, both of which are currently in clinical trials.
Progress in Clinical Trials
Imdusiran has already shown compelling clinical data regarding its effectiveness in reducing surface antigens and reactivating immune responses to the virus. It is currently involved in two Phase 2a combination clinical trials, highlighting the promising future of this therapeutic option. Meanwhile, AB-101 is advancing through a Phase 1a/1b clinical trial, demonstrating Arbutus’s dedication to innovation and patient care.
Contact Information for Inquiries
For more information, especially regarding investor relations, individuals can reach out to:
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Frequently Asked Questions
What is Arbutus Biopharma focused on?
Arbutus Biopharma specializes in developing treatments for chronic hepatitis B virus infections.
When are the upcoming investor conferences?
The conferences are scheduled for September 9 and September 10, 2024.
How can I access the conference presentations?
You can watch live webcasts during the conferences, which will also be archived for later viewing.
What treatments are currently in Arbutus's pipeline?
Arbutus is developing imdusiran (AB-729) and AB-101, both of which are currently undergoing clinical trials.
How can I contact Arbutus for more information?
You can reach Lisa M. Caperelli at 215-206-1822 or via email at lcaperelli@arbutusbio.com.
